Search Filters

Search Results

Found 3 results

510(k) Data Aggregation

    K Number
    K243065
    Device Name
    Cardiac Guidance
    Date Cleared
    2025-01-15

    (110 days)

    Product Code
    Regulation Number
    892.2100
    Reference & Predicate Devices
    Why did this record match?
    Reference Devices :

    DEN190040, K201992

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Cardiac Guidance software is intended to assist medical professionals in the acquisition of cardiac ultrasound images. Cardiac Guidance software is an accessory to compatible general purpose diagnostic ultrasound systems.

    The Cardiac Guidance software is indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) for adult patients, specifically in the acquisition of the following standard views: Parasternal Long-Axis (PLAX), Parasternal Short-Axis at the Aortic Valve (PSAX-AV), Parasternal Short-Axis at the Mitral Valve (PSAX-MV). Parasternal Short-Axis at the Papillary Muscle (PSAX-PM), Apical 4-Chamber (AP4), Apical 5-Chamber (AP5), Apical 2-Chamber (AP2), Apical 3-Chamber (AP3), Subcostal 4-Chamber (SubC4), and Subcostal Inferior Vena Cava (SC-IVC).

    Device Description

    The Cardiac Guidance software is a radiological computer-assisted acquisition guidance system that provides real-time guidance during echocardiography to assist the user capture anatomically correct images representing standard 2D echocardiographic diagnostic views and orientations. This Al-powered, software-only device emulates the expertise of skilled sonographers.

    Cardiac Guidance is comprised of several different features that, combined, provide expert guidance to the user. These include:

    • Quality Meter: The real-time feedback from the Quality Meter advises the user on the expected diagnostic quality of the resulting clip, such that the user can make decisions to further optimize the quality, for example by following the prescriptive guidance feature below.
    • Prescriptive Guidance: The prescriptive guidance feature in Cardiac Guidance provides direction to the user to emulate how a sonographer would manipulate the transducer to acquire the optimal view.
    • Auto-Capture: The Cardiac Guidance Auto-Capture feature triggers an automatic capture of a clip when the quality is predicted to be diagnostic, emulating the way in which a sonographer knows when an image is of sufficient quality to be diagnostic and records it.
    • Save Best Clip: This feature continually assesses clip quality while the user is scanning and, in the event that the user is not able to obtain a clip sufficient for Auto-Capture, the software allows the user to retrospectively record the highest quality clip obtained so far, mimicking the choice a sonographer might make when recording an exam.
    AI/ML Overview

    The provided document is a 510(k) summary for Cardiac Guidance software, which is a radiological computer-assisted acquisition guidance system. It discusses an updated Predetermined Change Control Plan (PCCP) and addresses how future modifications will be validated. However, it does not contain a detailed performance study with specific acceptance criteria and results from such a study for the current submission.

    The document focuses on the plan for future modifications and ensuring substantial equivalence through predefined testing. While it mentions that "Safety and performance of the Cardiac Guidance software will be evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing outlined in the submission," and "The test methods specified in the PCCP establish substantial equivalence to the predicate device, and include sample size determination, analysis methods, and acceptance criteria," the specific details of a study proving the device meets acceptance criteria are not included in this document.

    Therefore, the following information cannot be fully extracted based solely on the provided text:

    • A table of acceptance criteria and reported device performance (for the current submission/PCCP update).
    • Sample size used for the test set and data provenance.
    • Number of experts and their qualifications for establishing ground truth for the test set.
    • Adjudication method for the test set.
    • Results of a multi-reader multi-case (MRMC) comparative effectiveness study, including effect size.
    • Details of a standalone (algorithm only) performance study.
    • The type of ground truth used.
    • Sample size for the training set.
    • How the ground truth for the training set was established.

    However, the document does contain information about performance testing and acceptance criteria for future modifications under the PCCP.

    Here's a summary of what can be extracted or inferred regarding performance and validation, specifically related to the plan for demonstrating that future modifications will meet acceptance criteria:


    1. A table of Acceptance Criteria and the Reported Device Performance:

    The document describes the types of testing and the intent to use acceptance criteria for future modifications. It does not provide a table of acceptance criteria and reported device performance for the current submission or previous clearances. It states:

    "The test methods specified in the PCCP establish substantial equivalence to the predicate device, and include sample size determination, analysis methods, and acceptance criteria."

    This indicates that acceptance criteria will be defined for future validation tests, but they are not listed here. The document focuses on the types of modifications and the high-level testing methods:

    Modification CategoryTesting Methods Summary
    Retraining/optimization/modification of core algorithm(s)Repeating verification tests and the system level validation test to ensure the pre-defined acceptance criteria are met.
    Real-time guidance for additional 2D TTE viewsRepeating verification tests and two system level validation tests, including usability testing, to ensure the pre-defined acceptance criteria are met for the additional views.
    Optimization of the core algorithm(s) implementation (thresholds, averaging logic, transfer functions, frequency, refresh rate)Repeating relevant verification test(s) and the system level validation test to ensure the pre-defined acceptance criteria are met.
    Addition of new types of prescriptive guidance (patient positioning, breathing guidance, combined probe movements, pressure, sliding/angling) and addition of existing guidance types to all viewsRepeating relevant verification tests and two system level validation tests, including usability testing, to ensure the pre-defined acceptance criteria are met.
    Labeling compatibility with various screen sizes (including mobile) and UI/UX changes (e.g., audio, configurability of guidance)Repeating relevant verification tests and the system level validation test, including usability testing, to ensure the pre-defined acceptance criteria are met.

    2. Sample size used for the test set and the data provenance:

    The document states:

    "To ensure validation test datasets are representative of the intended use population, each will meet minimum demographic requirements."

    However, specific sample sizes and data provenance (e.g., country of origin, retrospective/prospective) for any performance study are not provided in this document. It only refers to "sample size determination" as being included in the test methods for the PCCP.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

    This information is not provided in the document.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

    This information is not provided in the document.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance:

    The document refers to a "Non-expert Validation" being added to the subject PCCP, which was "Not included" in the K201992 PCCP. It describes this as:

    "Adds standalone test protocol to enable validation of modified device performance by the intended user groups, ensuring equivalency to the original device based on predefined clinical endpoints."

    While this suggests a study involving users, it does not explicitly state it's an MRMC comparative effectiveness study comparing human readers with and without AI assistance, nor does it provide any effect size.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

    The document's "Testing Methods" column frequently mentions "Repeating verification tests and the system level validation test to ensure the pre-defined acceptance criteria are met." This suggests that standalone algorithm performance testing (verification and system-level validation) is part of the plan for future modifications. However, specific details of such a study are not provided in this document.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

    This information is not explicitly stated in the document. The "Non-expert Validation" mentions "predefined clinical endpoints," but the source of the ground truth for those endpoints is not detailed.

    8. The sample size for the training set:

    This information is not provided in the document.

    9. How the ground truth for the training set was established:

    This information is not provided in the document. The document mentions "Retraining/optimization/modification of core algorithm(s)" and that "The modification protocol incorporates impact assessment considerations and specifies requirements for data management, including data sources, collection, storage, and sequestration, as well as documentation and data segregation/re-use practices," implying a training set exists, but details on ground truth establishment are missing.

    Ask a Question

    Ask a specific question about this device

    K Number
    K240053
    Device Name
    Venue Go
    Date Cleared
    2024-06-10

    (154 days)

    Product Code
    Regulation Number
    892.1550
    Why did this record match?
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Venue Go is a general purpose diagnostic ultrasound system for use by qualified and trained healthcare professionals or practitioners that are legally authorized or licensed by law in the country, state or other local municipality in which he or she practices, for ultrasound imaging, measurement, display and analysis of the human body and fluid. The users may or may not be working under supervision or authority of a physician. Users may also include medical students working under the supervision or authority of a physician during their education / training. Venue Go is intended to be used in a hospital or medical clinic. Venue Go clinical applications include: abdominal (GYN and Urology), thoracic/pleural, ophthalmic, Fetal/OB, Small Organ (including breast, testes, thyroid), Vascular/Peripheral vascular, neonatal and adult cephalic, pediatric, musculoskeletal (conventional and superficial), cardiac (adults and pediatric), Transrectal, Transvaginal, Transesophageal, Intraoperative (vascular) and interventional guidance (includes tissue biopsy, fluid drainage, vascular and non-vascular access). Modes of operation include: B, M, PW Doppler, CW Doppler, Color Doppler, Color M Doppler, Power Doppler, Harmonic Imaging, Coded Pulse and Combined modes: B/M, B/Color M, B/PWD, B/Color/PWD, B/Power/PWD, B/CWD, B/Color/CWD.

    Device Description

    Venue Go is a general-purpose diagnostic ultrasound system intended for use by qualified and trained healthcare professionals to evaluate the body by ultrasound imaging and fluid flow analysis.

    The Venue Go is a compact, portable system with a small footprint. The system can be hand carried using an integrated handle, placed on a horizontal surface, attached to a mobile cart or wall mounted. It has a high resolution color LCD monitor, with a simple, multi-touch user interface that makes the system intuitive. The system can be powered through an electrical wall outlet for long term use or from an internal battery for a short time with full functionality and scanning.

    The Venue Go utilizes a variety of linear, convex, and phased array transducers which provide high imaging performance and support standard acquisition modes. Compatible biopsy kits can be used for needle-guidance procedures.

    The system is capable of displaying the patient's ECG trace synchronized to the scanned image. This allows the user to view an image from a specific time of the ECG signal which is used as an input for gating during scanning. The ECG signal can be input directly from the patient or as an output from an ECG monitoring device. ECG information is not intended for monitoring or diagnosis.

    A barcode reader and RFID scanner are available as additional input devices. A roller bag will also be available for the customer to use when transporting the system.
    Venue Go is capable of wireless communication through a built-in Wireless LAN device. The system meets DICOM requirements to support image storage and archiving (local PACS or products such as Q-Path) and allows for output to printing devices.

    AI/ML Overview

    The provided FDA 510(k) summary for the GE Venue Go ultrasound system does not include acceptance criteria for artificial intelligence (AI) performance or the study details to prove the device meets such criteria.

    The document primarily focuses on demonstrating substantial equivalence to a predicate device (Venue Go K220800) and other reference devices, based on:

    • Identical fundamental scientific technology.
    • Similar imaging capabilities, technological characteristics, safety, and effectiveness.
    • Minor updates to the Indications for Use statement for clarity regarding operator qualifications.
    • Addition of new transducers already cleared on other GE devices.
    • New features/functionality such as Auto Volume Flow (AVF), Bladder Volume Tool, expanded MSK diagrams, Venue Coach, electronic software delivery, expanded Auto Inferior Vena Cava (IVC), Auto B-Lines, Real-Time ejection fraction (RT-EF), cNerve for Vscan Air CL and SL probes (which are already cleared with these AI features on predicate Vscan Air K231301 and reference LOGIQ E10s/LOGIQ Fortis K231989), and AppAPI functionality.
    • Conformity to recognized performance standards for acoustic output, biocompatibility, cleaning/disinfection, thermal, electrical, electromagnetic, and mechanical safety.
    • Quality assurance measures like risk analysis, requirements/design reviews, and various levels of testing.

    Specifically, the document states: "The subject of this premarket submission, Venue Go, did not require clinical studies to support substantial equivalence." This indicates that any evaluation of "AI performance" as typically understood (e.g., using a test set with ground truth, performance metrics, and acceptance criteria) was not part of this 510(k) submission.

    The AI-related features mentioned (Auto IVC, Auto B-Lines, RT-EF, cNerve) are noted as being "expanded" or already "cleared" on predicate/reference devices (K231301 Vscan Air, K231989 LOGIQ E10s/LOGIQ Fortis). This implies their performance was likely evaluated as part of those previous 510(k) submissions, and the current submission is leveraging that prior clearance for their inclusion in the Venue Go system when used with the particular probes.

    Therefore, since this 510(k) does not present new AI performance study data for the Venue Go, I cannot extract the requested information. The document focuses on demonstrating that the Venue Go, with its included features, is substantially equivalent to existing cleared devices, rather than proving novel AI algorithm performance.

    Ask a Question

    Ask a specific question about this device

    K Number
    K240111
    Device Name
    Venue
    Date Cleared
    2024-06-10

    (146 days)

    Product Code
    Regulation Number
    892.1550
    Reference & Predicate Devices
    Why did this record match?
    Reference Devices :

    Voluson S10/ Voluson S10 Expert, K202035 Vscan Air, K200851 Vivid T8, Vivid T9, K203677 ViewPoint 6, K201992

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Venue is a general purpose diagnostic ultrasound system for use by qualified and trained healthcare professionals or practitioners that are legally authorized or licensed by law in the country. state or other local municipality in which he or she practices, for ultrasound imaging, measurement. display and analysis of the human body and fluid. The users may or may not be working under supervision or authority of a physician. Users may also include medical students working under the supervision or authority of a physician during their education / training.

    Venue is intended to be used in a hospital or medical clinic. Venue clinical applications include: abdominal (GYN and Urology), thoracic/pleural, ophthalmic. Fetal/OB, Small Organ (including breast, testes, thyroid), Vascular/Peripheral vascular, neonatal and adult cephalic, pediatric, musculoskeletal (conventional and superficial), cardiac (adults and pediatric), Transrectal, Transvaginal, Transesophageal, Intraoperative (vascular) and interventional guidance (includes tissue biopsy, fluid drainage, vascular and non-vascular access). Modes of operation include: B. M. PW Doppler, CW Doppler, Color M Doppler, Color M Doppler, Harmonic Imaging, Coded Pulse and Combined modes: B/M, B/Color M, B/PWD, B/Color/PWD, B/Power/PWD,B/CWD, B/Color/CWD.

    Device Description

    The proposed Venue system is a general-purpose, Track 3, diagnostic ultrasound device, intended for ultrasound imaging, measurement and analysis of the human body and fluid that provides digital acquisition, processing and display capabilities. Venue can be used in offices, clinics and hospitals.

    The Venue is a mobile system with a small footprint that easily fits into tight spaces and positioned to accommodate the sometimes-awkward work settings of the point of care user.

    The Venue has a high resolution color LCD monitor, with a simple, multi-touch user interface that makes the system intuitive. The single surface screen provides easy cleanability. Articulated monitor arm enables flexible display positions in order to be accessible and clearly visible in both user-standing and sitting positions.

    The system is capable of displaying the patient's ECG trace synchronized to the scanned image. This allows the user to view an image from a specific time of the ECG signal which is used as an input for gating during scanning. The ECG signal can be input directly from the patient or as an output from an ECG monitoring device. ECG information is not intended for monitoring or diagnosis.

    Barcode reader and RFID scanner are available as additional input devices.

    The Venue has a battery that allows for scanning without the need to plug in to an electrical outlet.

    System meets DICOM requirements to support users image storage and archiving needs and allows for output to printing devices.

    The Venue utilizes a variety of linear, convex, and phased array transducers which provide high imaging capability, supporting all standard acquisition modes. Compatible biopsy kits can be used for needle-guidance procedures.

    The system includes several automated tools designed to simplify and shorten the workflow time of the healthcare professional for some common assessments.

    AI/ML Overview

    The provided document is a 510(k) Summary for a diagnostic ultrasound system (Venue). It does not contain information about acceptance criteria and a study that proves the device meets those criteria for software performance.

    The document states:

    • "The subject of this premarket submission, Venue, did not require clinical studies to support substantial equivalence." (Page 10)
    • The comparison is primarily focused on hardware, transducers, and general features, and states that the Venue system is substantially equivalent to a predicate device regarding "imaging capabilities, technological characteristics and safety and effectiveness." (Page 6)

    Therefore, I cannot extract the requested information regarding acceptance criteria, device performance, sample sizes, data provenance, expert qualifications, ground truth establishment, or multi-reader multi-case studies because this document does not present such a study. The submission focuses on demonstrating substantial equivalence to a predicate device, which often relies on non-clinical tests and comparisons rather than new clinical performance studies.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1